6 companies in Third Rock Ventures's investment portfolio.
Back to Third Rock Ventures profile“Creates and builds breakthrough biopharmaceutical companies by combining cutting-edge science with experienced drug development teams.”
Biotechnology company developing gene therapies for severe genetic diseases and cancer using advanced gene editing technologies.
Precision medicine company developing targeted therapies for cancer and rare diseases using genomics-based drug discovery.
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology.
Foundation Medicine, Inc. is an American company based in Boston, Massachusetts, which develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas.
A clinical-stage biopharmaceutical company focused on developing novel therapies for psychiatric and neurological conditions.
Clinical-stage biotech developing cancer treatments by controlling gene expression using proprietary gene control platforms.
Third Rock Ventures has built a portfolio of 6 companies across 1 sector, including Biotech.
The portfolio reflects investments across the IPO stage, showing Third Rock Ventures's approach to supporting companies at a focused stage of development.
Third Rock Ventures has invested in 6+ companies across 1 different sectors.
Third Rock Ventures's portfolio spans Biotech. This diversification reflects the firm's broad investment thesis and sector expertise.
Third Rock Ventures invests across the IPO stage. Their portfolio includes companies at various points in their growth journey.